Current Pain and Headache Reports

, Volume 16, Issue 4, pp 371–378 | Cite as

Headache and Temporal Arteritis: When to Suspect and How to Manage

Uncommon Headache Syndromes (ME Bigal, Section editor)

Abstract

Temporal arteritis, also termed giant cell arteritis, is one of the vasculitides affecting large and medium sized cranial arteries, particularly of the carotid tree. Clinical manifestations may vary from the classic constellation of temporal headache in the elderly accompanied by constitutional signs, jaw claudication, and visual symptoms; therefore, a high index of clinical suspicion may be necessary to identify the disorder. Once suspected, immediate treatment is crucial while exploring any number of diagnostic tools to confirm or refute the diagnosis, since morbidity from untreated temporal arteritis can be devastating. At the same time, achieving a definitive diagnosis is paramount, as treatment can be toxic with significant morbidity of its own. Temporal artery biopsy remains the gold standard, but noninvasive diagnostic approaches are being refined. Corticosteroids remain the cornerstone of treatment, but are ineffective for, not tolerated by, or contraindicated in some individuals, necessitating the exploration of alternatives.

Keywords

Headache Secondary headache Temporal arteritis Giant cell arteritis Vasculitis Temporal artery biopsy Diagnosis Treatment 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Horton BT, Magath BT, Brown GE. Arteritis of the temporal vessels: report of 7 cases. Proc Staff Meet Mayo Clin. 1937;12:548–53.Google Scholar
  2. 2.
    •• Gonzalez-Gay MA, Martinez-Dubois C, Agudo M, Pompei O, Blanco R, Llorca J. Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep. 2010;12(6):436–42. This is a comprehensive review.PubMedCrossRefGoogle Scholar
  3. 3.
    Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. 2004;24:9–160.CrossRefGoogle Scholar
  4. 4.
    Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. 2010;49(8):1594–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Dodick DW. Pearls: headache. Semin Neurol. 2010;30(1):74–81.PubMedCrossRefGoogle Scholar
  7. 7.
    • Kermani TA, Schäfer VS, Crowson CS, Hunder GG, Gabriel SE, Matteson EL, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010;69(4):780–1. The Olmsted County data reflect an increased incidence in individuals over age 70 years.PubMedCrossRefGoogle Scholar
  8. 8.
    Salvarani C, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Care Res. 2004;51(2):264–8.CrossRefGoogle Scholar
  9. 9.
    •• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Care Res. 2009;61(10):1454–61. This is a review of geographic and phenomenological differences in epidemiology, including the influence of environmental and genetic factors.CrossRefGoogle Scholar
  10. 10.
    • Liozon E, Ouattara B, Rhaiem K, Ly K, Bezanahary H, Loustaud V, et al. Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families. Clin Exp Rheumatol. 2009;27(1 Suppl 52):S89–94. The theory of a genetic predisposition to TA is defended in this article.PubMedGoogle Scholar
  11. 11.
    Ward TN, Levin M. Headache in giant cell arteritis and other arteritides. Neurol Sci. 2005;26 Suppl 2:S134–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Cullen JF, Coleiro JA. Ophthalmic complications of giant cell arteritis. Surv Ophthalmol. 1976;20(4):247–60.PubMedCrossRefGoogle Scholar
  13. 13.
    •• Kale N, Eggenberger E. Diagnosis and management of giant cell arteritis: a review. Curr Opin Ophthalmol. 2010;21(6):417–22. This review focuses on clinical features and addresses novel treatment options.PubMedCrossRefGoogle Scholar
  14. 14.
    Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287(1):92–101.PubMedCrossRefGoogle Scholar
  15. 15.
    •• Villa-Forte A. Giant cell arteritis: suspect it, treat it promptly. Cleve Clin J Med. 2011;78(4):265–70. This is a highly practical and useful review of the approach to patients with potential TA.PubMedCrossRefGoogle Scholar
  16. 16.
    Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine. 2005;84(5):269–76.PubMedCrossRefGoogle Scholar
  17. 17.
    Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 1998;41(7):1221–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum. 1995;24(6):422–31.PubMedCrossRefGoogle Scholar
  19. 19.
    Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122(7):502–7.PubMedGoogle Scholar
  20. 20.
    Tatò F, Hoffmann U. Giant cell arteritis: a systemic vascular disease. Vasc Med. 2008;13(2):127–40.PubMedCrossRefGoogle Scholar
  21. 21.
    •• Kermani TA, Warrington KJ. Recent advances in diagnostic strategies for giant cell arteritis. Curr Neurol Neurosci Rep. 2012;12:138–44. This excellent review summarizes diagnosis with particular attention to a critical analysis of imaging modalities in temporal arteritis.Google Scholar
  22. 22.
    Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol. 2003;21(6 Suppl 32):S23–8.PubMedGoogle Scholar
  23. 23.
    Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, Peña-Sagredo JL, Martin J, Gonzalez-Gay MA. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum. 2008;38(2):116–23.PubMedCrossRefGoogle Scholar
  24. 24.
    Parikh M, Miller NR, Lee AG, Savino PJ, Vacarezza MN, Cornblath W, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006;113(10):1842–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. 2004;14(3):245–57.PubMedGoogle Scholar
  26. 26.
    Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy. Ophthalmology. 2011;118(6):1201–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Schmidt WA, Kraft HE, Vorpahl K, Völker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337(19):1336–42.PubMedCrossRefGoogle Scholar
  28. 28.
    Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JPA. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005;142(5):359–69.PubMedGoogle Scholar
  29. 29.
    • Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord. 2010;11:44. This meta-analysis confirms the utility of the halo sign.Google Scholar
  30. 30.
    Karahaliou M, Vaiopoulos G, Papaspyrou S, Kanakis MA, Revenas K, Sfikakis PP. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther. 2006;8(4):R116.Google Scholar
  31. 31.
    Geiger J, Bley T, Uhl M, Frydrychowicz A, Langer M, Markl M. Diagnostic value of T2-weighted imaging for the detection of superficial cranial artery inflammation in giant cell arteritis. J Magn Reson Imaging. 2010;31(2):470–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Both M, Ahmadi-Simab K, Reuter M, Dourvos O, Fritzer E, Ullrich S, et al. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann Rheum Dis. 2008;67(7):1030–3.PubMedCrossRefGoogle Scholar
  33. 33.
    Tso E, Flamm SD, White RD, Schvartzman PR, Mascha E, Hoffman GS. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum. 2002;46(6):1634–42.PubMedCrossRefGoogle Scholar
  34. 34.
    Bley TA, Uhl M, Carew J, Markl M, Schmidt D, Peter H, et al. Diagnostic value of high-resolution MR imaging in giant cell arteritis. AJNR Am J Neuroradiol. 2007;28(9):1722–7.PubMedCrossRefGoogle Scholar
  35. 35.
    • Bley TA, Reinhard M, Hauenstein C, Markl M, Warnatz K, Hetzel A, et al. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum. 2008;58(8):2574–8. This study promotes the notion that ultrasound and magnetic resonance imaging are comparable.PubMedCrossRefGoogle Scholar
  36. 36.
    Lefebvre C, Rance A, Paul J, Beguin C, Bletry O, Amoura Z, et al. The role of B-mode ultrasonography and electron beam computed tomography in evaluation of Takayasu’s arteritis: a study of 43 patients. Semin Arthritis Rheum. 2000;30(1):25–32.PubMedCrossRefGoogle Scholar
  37. 37.
    Chung JW, Kim H, Choi YH, Kim SJ, Lee W, Park JH. Patterns of aortic involvement in Takayasu arteritis and its clinical implications: evaluation with spiral computed tomography angiography. J Vasc Surg. 2007;45(5):906–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Brodmann M, Lipp RW, Passath A, Seinost G, Pabst E, Pilger E. The role of 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. Rheumatology. 2004;43(2):241–2.PubMedCrossRefGoogle Scholar
  39. 39.
    Lehmann P, Buchtala S, Achajew N, Haerle P, Ehrenstein B, Lighvani H, et al. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin Rheumatol. 2011;30(1):37–42.PubMedCrossRefGoogle Scholar
  40. 40.
    • Besson FL, Parienti J, Bienvenu B, Prior JO, Costo S, Bouvard G, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38(9):1764–72. Six controlled studies of PET in the evaluation of TA are analyzed in this article, with particular attention to diagnostic characteristics.PubMedCrossRefGoogle Scholar
  41. 41.
    Henes JC, Müller M, Krieger J, Balletshofer B, Pfannenberg AC, Kanz L, et al. [18F] FDG-PET/CT as a new and sensitive imaging method for the diagnosis of large vessel vasculitis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S47–52.PubMedGoogle Scholar
  42. 42.
    Niederkohr RD, Levin LA. A Bayesian analysis of the true sensitivity of a temporal artery biopsy. Invest Ophthalmol Vis Sci. 2007;48(2):675–80.PubMedCrossRefGoogle Scholar
  43. 43.
    • Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318–23. This review details management strategies.PubMedCrossRefGoogle Scholar
  44. 44.
    Marí B, Monteagudo M, Bustamante E, Pérez J, Casanovas A, Jordana R, et al. Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med. 2009;20(5):533–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Breuer GS, Nesher G, Nesher R. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol. 2009;36(4):794–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999;128(2):211–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42(2):311–7.PubMedCrossRefGoogle Scholar
  48. 48.
    • Breuer GS, Nesher R, Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol. 2009;27(1 Suppl 52):S10–3. This paper provides evidence that biopsies shorter than 5 mm are inadequate, and explains why biopsies of 20 mm or longer are desirable.PubMedGoogle Scholar
  49. 49.
    Ray-Chaudhuri N, Ah Kiné D, Tijani SO, Parums DV, Cartlidge N, Strong NP, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002;86(5):530–2.PubMedCrossRefGoogle Scholar
  50. 50.
    Foroozan R, Deramo VA, Buono LM, Jayamanne DGR, Sergott RC, Danesh-Meyer H, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003;110(3):539–42.PubMedCrossRefGoogle Scholar
  51. 51.
    Neff AG, Greifenstein EM. Giant cell arteritis update. Semin Ophthalmol. 1999;14(2):109–12.PubMedCrossRefGoogle Scholar
  52. 52.
    González-Gay MA, Blanco R, Rodríguez-Valverde V, Martínez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41(8):1497–504.PubMedCrossRefGoogle Scholar
  53. 53.
    Chew SSL, Kerr NM, Danesh-Meyer HV. Giant cell arteritis. J Clin Neurosci. 2009;16(10):1263–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum. 2002;46(2):457–66.PubMedCrossRefGoogle Scholar
  56. 56.
    Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54(10):3306–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Narváez FJG, Bernad B, Gómez-Vaquero C, García-Gómez C, Roig-Vilaseca D, Juanola X, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S57–62.PubMedGoogle Scholar
  59. 59.
    Salvarani C, Della Bella C, Cimino L, Macchioni P, Formisano D, Bajocchi G. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology. 2009;48(3):250–3.PubMedCrossRefGoogle Scholar
  60. 60.
    • Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology. 2009;48(3):258–61. This article, along with references 5559, underscores the importance of vigilance for vascular risk factors and the potential benefit of antiplatelet therapy.PubMedCrossRefGoogle Scholar
  61. 61.
    Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, LaValley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–97.PubMedCrossRefGoogle Scholar
  62. 62.
    Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309–18.PubMedCrossRefGoogle Scholar
  63. 63.
    Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MGE, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495–501.PubMedGoogle Scholar
  64. 64.
    Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106–14.PubMedGoogle Scholar
  65. 65.
    Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621–30.PubMedGoogle Scholar
  66. 66.
    Devauchelle-Pensec V, Jousse S, Destombe C, Saraux A. Epidemiology, imaging, and treatment of giant cell arteritis. Joint Bone Spine. 2008;75(3):267–72.PubMedCrossRefGoogle Scholar
  67. 67.
    • Martínez-Valle F, Solans-Laqué R, Bosch-Gil J, Vilardell-Tarrés M. Aortic involvement in giant cell arteritis. Autoimmun Rev. 2010;9(7):521–4. This article details that early recognition of aortic involvement in TA is paramount to avoid serious morbidity.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of NeurologyThomas Jefferson University Hospital, Jefferson Headache CenterPhiladelphiaUSA

Personalised recommendations